RxDoctor Payments Data

Viswanath Kalapatapu, MD

Internal Medicine · Katy, TXNPI 1972549061

Payments from drug & device makers

$12,471in general payments, 2019–2025

Across 745 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Johnson & Johnson$889
  • GSK$834
  • Amgen$699
  • Boehringer Ingelheim$673
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,465100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,471 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$223,869
Medicare patients
381
Services billed
3,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$117,465
EliquisApixaban79$86,522
JardianceEmpagliflozin65$76,855
FarxigaDapagliflozin Propanediol60$67,845
MounjaroTirzepatide33$39,797
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$31,322
XareltoRivaroxaban26$26,683
RybelsusSemaglutide13$19,293
MyrbetriqMirabegron31$18,562
JanuviaSitagliptin Phosphate14$16,064
TradjentaLinagliptin14$10,263
GemtesaVibegron15$10,050
Tresiba Flextouch U-100Insulin Degludec12$4,976
Levothyroxine Sodium418$4,771
Mesalamine34$4,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,729$136,758112 claims
Boehringer IngelheimJardiance, Tradjenta$673$87,11879 claims
PfizerEliquis$474$86,52279 claims
AstraZenecaFarxiga$1,869$67,84560 claims
Lilly USA, LLCMounjaro$521$39,79733 claims
GSKTrelegy Ellipta$834$31,32229 claims
Johnson & JohnsonXarelto$889$26,68326 claims
Astellas Pharma US IncMyrbetriq$386$18,56231 claims
MerckJanuvia$462$16,06414 claims
Sumitomo Pharma America, Inc.Gemtesa$248$10,05015 claims
AbbVieSynthroid$74$4,19269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →